Webinar: Developability Assessment: Why, What, and How скачать в хорошем качестве

Webinar: Developability Assessment: Why, What, and How

Webinar: Developability Assessment: Why, What, and How In collaboration with the Antibody Society, Brady Wu, PhD, Head of Protein Center at Biointron describes developability as an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates. Seminar Objectives: • How developability guides real-world projects. From optimizing machine learning algorithms with AI to enabling stability-driven antibody engineering, developability insights are becoming deeply embedded in discovery workflows. As our understanding evolves, so too will its role in shaping the future of drug development. • Why developability assessments are essential at multiple stages. As biologics grow more complex, early evaluation is key to identifying promising leads. Evidence shows clear correlations between developability parameters and pharmacokinetic (PK) behavior. • What developability entails. It refers to key biophysical properties such as hydrophobicity, thermal stability, colloidal stability, non-specific binding, and surface charge that collectively inform candidate viability. Our comprehensive assessments complement functional data to support lead selection. About the Speaker: Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China’s top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company. *** Find us elsewhere: LinkedIn:   / biointron   Facebook:   / biointron2012   Twitter:   / biointron2012   About Biointron: Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Until now, Biointron has delivered tens of thousands of recombinant antibodies for more than 2,500 biotech and pharma companies all over the world. Founded in 2012 | Certified to ISO 9001:2015 | High-technology enterprises CRO supplier for antibody discovery, expression, and optimization